Beta Bionics Cuts 2026 Revenue Guidance, Discloses Securities Class Action Alongside Mint FDA Clearance
BBNX has more than doubled off its 52-week low of $8.8.
Summary
Beta Bionics received FDA clearance for its Mint patch pump and submitted a 510(k) for its 3D Intelligence algorithm, but simultaneously cut 2026 revenue guidance by $10 million and disclosed a securities class action lawsuit filed September 4, 2026.
Key Events · Product Development and Regulatory · BBNX
-
Mint Patch Pump Receives FDA Clearance
FDA cleared Mint, a patch pump with reusable-disposable architecture, no recharging requirement, and smartphone control for iOS and Android. Full U.S. commercial launch expected Q1 2027.
-
2026 Revenue Guidance Cut by $10M
Full-year 2026 revenue guidance lowered to $121M-$126M from $131M-$136M, driven by up to $10M in Q4 revenue deferral as prospective iLet users await the Mint launch.
-
Securities Class Action Filed
A purported stockholder filed a securities class action on September 4, 2026 (Holtzman vs. Beta Bionics, Inc. et al.) alleging violations of Sections 10(b) and 20(a) regarding statements about iLet's safety, efficacy, and commercial success. Company intends to vigorously defend.
-
3D Intelligence 510(k) Submitted to FDA
Beta Bionics submitted a 510(k) application for 3D Intelligence, its next-generation insulin dosing algorithm with three selectable experiences (Original, Optimized, Conservative). Commercialization expected by end of 2026 as iLet 3D, subject to FDA clearance.
Analysis · BBNX · Industrial Applications And Services
The FDA clearance of the Mint patch pump and the 510(k) submission for the 3D Intelligence algorithm mark important product milestones, but the filing also carries two significant negatives. Full-year 2026 revenue guidance was cut by $10 million at the midpoint to $121M-$126M, as prospective iLet users defer purchases awaiting Mint. Additionally, a securities class action was filed on September 4, 2026, alleging misstatements about iLet's safety, efficacy, and commercial success. The guidance cut signals near-term revenue disruption from the company's own product transition, while the lawsuit adds legal overhang and potential defense costs. The Mint clearance itself is a major positive milestone that expands the addressable market into the patch pump segment, with manufacturing capacity targeted at 1.5 million disposable units in 2027 and pharmacy channel coverage expected to reach 50% of insured U.S. lives within the first year.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 35.7% of the 1179 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.44%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BBNX was trading at $18.47 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $865.2M. The 52-week trading range was $8.80 to $32.71. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.